GlassScriptPhysician profile
Danielle L Magness-Wellmann
NPI 1679729164
$232,459.06
in general payments reported to CMS, 2019-2025
26 companies · $71K in 2025
The $71K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,450 · 2020: $2,588 · 2021: $9,172 · 2022: $7,254 · 2023: $63K · 2024: $75K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $118K · Consulting Fee: $41K · Honoraria: $25K · Travel and Lodging: $19K · Food and Beverage: $4,497 · Education: $32.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $118,434.50 |
| Consulting Fee | $41,151.00 |
| Honoraria | $24,950.00 |
| Travel and Lodging | $18,930.89 |
| Food and Beverage | $4,497.31 |
| Education | $32.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $56,457.23 | 2023-2025 | Auvelity, Sunosi |
| Abbvie INC. | $55,847.06 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $44,974.77 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $28,933.20 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21,724.81 | 2022-2025 | Caplyta |
| Allergan, INC. | $8,572.51 | 2019-2021 | |
| Tris Pharma INC | $7,195.27 | 2019-2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Biogen, INC. | $6,684.00 | 2024-2025 | Zurzuvae |
| Sunovion Pharmaceuticals INC. | $1,186.93 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $120.05 | 2024-2025 | Qelbree |
| Acadia Pharmaceuticals INC | $112.37 | 2019-2025 | Nuplazid |
| Corium, LLC | $109.72 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $96.95 | 2019-2024 | |
| Harmony Biosciences LLC | $95.96 | 2021-2025 | Wakix |
| Vanda Pharmaceuticals INC. | $70.96 | 2024-2025 | Fanapt |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $63.26 | 2019-2022 | |
| Almatica Pharma LLC | $40.30 | 2021-2022 | |
| Sage Therapeutics, LLC | $34.50 | 2024-2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $32.55 | 2022-2024 | Trintellix |
| Eisai INC. | $29.79 | 2020-2021 | |
| Indivior INC. | $20.20 | 2024 | Sublocade |
| Novo Nordisk INC | $15.26 | 2023 | |
| Jazz Pharmaceuticals INC. | $15.23 | 2025 | |
| Neurocrine Biosciences, INC. | $13.54 | 2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $12.64 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Magness-Wellmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.